2020 Q1 Form 10-Q Financial Statement
#000156459020022416 Filed on May 07, 2020
Income Statement
| Concept | 2020 Q1 | 2019 Q1 |
|---|---|---|
| Revenue | $1.262M | $1.347M |
| YoY Change | -6.31% | |
| Cost Of Revenue | ||
| YoY Change | ||
| Gross Profit | ||
| YoY Change | ||
| Gross Profit Margin | ||
| Selling, General & Admin | $5.470M | $4.380M |
| YoY Change | 24.89% | 114.71% |
| % of Gross Profit | ||
| Research & Development | $22.47M | $15.90M |
| YoY Change | 41.32% | 39.45% |
| % of Gross Profit | ||
| Depreciation & Amortization | $1.630M | $1.040M |
| YoY Change | 56.73% | 14.29% |
| % of Gross Profit | ||
| Operating Expenses | $27.93M | $20.28M |
| YoY Change | 37.76% | 50.87% |
| Operating Profit | -$26.67M | -$18.93M |
| YoY Change | 40.9% | 40.85% |
| Interest Expense | $465.0K | $920.0K |
| YoY Change | -49.46% | 1360.32% |
| % of Operating Profit | ||
| Other Income/Expense, Net | ||
| YoY Change | ||
| Pretax Income | -$26.21M | -$18.01M |
| YoY Change | 45.53% | 34.6% |
| Income Tax | ||
| % Of Pretax Income | ||
| Net Earnings | -$26.21M | -$18.01M |
| YoY Change | 45.52% | 34.64% |
| Net Earnings / Revenue | -2076.55% | -1336.97% |
| Basic Earnings Per Share | -$0.71 | |
| Diluted Earnings Per Share | -$0.71 | -$622.3K |
| COMMON SHARES | ||
| Basic Shares Outstanding | 36.80M | 29.19M |
| Diluted Shares Outstanding | 36.80M |
Balance Sheet
| Concept | 2020 Q1 | 2019 Q1 |
|---|---|---|
| SHORT-TERM ASSETS | ||
| Cash & Short-Term Investments | $108.9M | $132.2M |
| YoY Change | -17.62% | |
| Cash & Equivalents | $55.85M | $34.57M |
| Short-Term Investments | $54.00M | $97.60M |
| Other Short-Term Assets | $367.0K | $500.0K |
| YoY Change | -26.6% | |
| Inventory | ||
| Prepaid Expenses | ||
| Receivables | ||
| Other Receivables | ||
| Total Short-Term Assets | $112.3M | $135.0M |
| YoY Change | -16.81% | |
| LONG-TERM ASSETS | ||
| Property, Plant & Equipment | $48.00M | $15.65M |
| YoY Change | 206.67% | |
| Goodwill | ||
| YoY Change | ||
| Intangibles | ||
| YoY Change | ||
| Long-Term Investments | ||
| YoY Change | ||
| Other Assets | $2.700M | $250.0K |
| YoY Change | 980.0% | |
| Total Long-Term Assets | $50.70M | $40.49M |
| YoY Change | 25.23% | |
| TOTAL ASSETS | ||
| Total Short-Term Assets | $112.3M | $135.0M |
| Total Long-Term Assets | $50.70M | $40.49M |
| Total Assets | $163.0M | $175.5M |
| YoY Change | -7.12% | |
| SHORT-TERM LIABILITIES | ||
| YoY Change | ||
| Accounts Payable | $5.000M | $3.622M |
| YoY Change | 38.05% | |
| Accrued Expenses | $8.900M | $803.0K |
| YoY Change | 1008.34% | |
| Deferred Revenue | $5.419M | |
| YoY Change | ||
| Short-Term Debt | $0.00 | $0.00 |
| YoY Change | ||
| Long-Term Debt Due | ||
| YoY Change | ||
| Total Short-Term Liabilities | $18.40M | $14.11M |
| YoY Change | 30.39% | |
| LONG-TERM LIABILITIES | ||
| Long-Term Debt | $0.00 | $0.00 |
| YoY Change | ||
| Other Long-Term Liabilities | $29.20M | $2.000K |
| YoY Change | 1459900.0% | |
| Total Long-Term Liabilities | $29.20M | $2.000K |
| YoY Change | 1459900.0% | |
| TOTAL LIABILITIES | ||
| Total Short-Term Liabilities | $18.40M | $14.11M |
| Total Long-Term Liabilities | $29.20M | $2.000K |
| Total Liabilities | $47.63M | $43.27M |
| YoY Change | 10.09% | |
| SHAREHOLDERS EQUITY | ||
| Retained Earnings | -$247.2M | -$144.6M |
| YoY Change | 70.99% | |
| Common Stock | $17.00K | $16.00K |
| YoY Change | 6.25% | |
| Preferred Stock | ||
| YoY Change | ||
| Treasury Stock (at cost) | ||
| YoY Change | ||
| Treasury Stock Shares | ||
| Shareholders Equity | $115.4M | $132.2M |
| YoY Change | ||
| Total Liabilities & Shareholders Equity | $163.0M | $175.5M |
| YoY Change | -7.11% |
Cashflow Statement
| Concept | 2020 Q1 | 2019 Q1 |
|---|---|---|
| OPERATING ACTIVITIES | ||
| Net Income | -$26.21M | -$18.01M |
| YoY Change | 45.52% | 34.64% |
| Depreciation, Depletion And Amortization | $1.630M | $1.040M |
| YoY Change | 56.73% | 14.29% |
| Cash From Operating Activities | -$22.98M | -$19.13M |
| YoY Change | 20.13% | 27.01% |
| INVESTING ACTIVITIES | ||
| Capital Expenditures | $1.609M | $2.578M |
| YoY Change | -37.59% | 52.36% |
| Acquisitions | ||
| YoY Change | ||
| Other Investing Activities | $16.38M | $4.010M |
| YoY Change | 308.48% | -46.32% |
| Cash From Investing Activities | $14.77M | $1.430M |
| YoY Change | 933.15% | -75.25% |
| FINANCING ACTIVITIES | ||
| Cash Dividend Paid | ||
| YoY Change | ||
| Common Stock Issuance & Retirement, Net | $5.659M | $86.00K |
| YoY Change | 6480.23% | 855.56% |
| Debt Paid & Issued, Net | ||
| YoY Change | ||
| Cash From Financing Activities | 5.655M | 86.00K |
| YoY Change | 6475.58% | 855.56% |
| NET CHANGE | ||
| Cash From Operating Activities | -22.98M | -19.13M |
| Cash From Investing Activities | 14.77M | 1.430M |
| Cash From Financing Activities | 5.655M | 86.00K |
| Net Change In Cash | -2.548M | -17.61M |
| YoY Change | -85.53% | 89.92% |
| FREE CASH FLOW | ||
| Cash From Operating Activities | -$22.98M | -$19.13M |
| Capital Expenditures | $1.609M | $2.578M |
| Free Cash Flow | -$24.59M | -$21.71M |
| YoY Change | 13.27% | 29.57% |
Facts In Submission
| Frame | Concept Type | Concept / XBRL Key | Value | Unit |
|---|---|---|---|---|
| CY2020Q1 | us-gaap |
Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
|
20101000 | |
| CY2020Q1 | us-gaap |
Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
|
9088000 | |
| CY2020Q1 | us-gaap |
Liabilities
Liabilities
|
47629000 | |
| CY2020Q1 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
||
| CY2020Q1 | us-gaap |
Preferred Stock Value
PreferredStockValue
|
0 | |
| CY2020Q1 | us-gaap |
Common Stock Value
CommonStockValue
|
17000 | |
| CY2020Q1 | us-gaap |
Additional Paid In Capital
AdditionalPaidInCapital
|
362586000 | |
| CY2020Q1 | us-gaap |
Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
|
-20000 | |
| CY2020Q1 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-247194000 | |
| CY2020Q1 | us-gaap |
Stockholders Equity
StockholdersEquity
|
115389000 | |
| CY2020Q1 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
163018000 | |
| CY2020Q1 | us-gaap |
Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
|
0.0001 | |
| CY2020Q1 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
10000000 | |
| CY2020Q1 | us-gaap |
Preferred Stock Shares Issued
PreferredStockSharesIssued
|
0 | |
| CY2020Q1 | us-gaap |
Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
|
0 | |
| CY2020Q1 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.0001 | |
| CY2020Q1 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-22977000 | |
| CY2020Q1 | grts |
Increase Decrease In Lease Liability
IncreaseDecreaseInLeaseLiability
|
-520000 | |
| CY2019Q1 | grts |
Increase Decrease In Lease Liability
IncreaseDecreaseInLeaseLiability
|
-640000 | |
| CY2020Q1 | us-gaap |
Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
|
-917000 | |
| CY2020Q1 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
300000000 | |
| CY2020Q1 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
36985739 | |
| CY2020Q1 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
36985739 | |
| CY2020Q1 | us-gaap |
Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
|
1262000 | |
| CY2020Q1 | us-gaap |
Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
|
us-gaap:LicenseMember | |
| CY2019Q1 | us-gaap |
Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
|
us-gaap:LicenseMember | |
| CY2020Q1 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
22468000 | |
| CY2019Q1 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
15899000 | |
| CY2020Q1 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
5465000 | |
| CY2019Q1 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
4377000 | |
| CY2019Q1 | us-gaap |
Operating Expenses
OperatingExpenses
|
20276000 | |
| CY2020Q1 | us-gaap |
Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
|
465000 | |
| CY2020Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-26206000 | |
| CY2019Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-18009000 | |
| CY2020Q1 | us-gaap |
Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
|
-44000 | |
| CY2019Q1 | us-gaap |
Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
|
152000 | |
| CY2020Q1 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-26250000 | |
| CY2019Q1 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-17857000 | |
| CY2020Q1 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.71 | |
| CY2019Q1 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.62 | |
| CY2020Q1 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
36798562 | |
| CY2019Q1 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
28938891 | |
| CY2020Q1 | us-gaap |
Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
|
5577000 | |
| CY2020Q1 | grts |
Lapse Of Repurchase Rights Related To Common Stock Issued Pursuant To Early Exercises
LapseOfRepurchaseRightsRelatedToCommonStockIssuedPursuantToEarlyExercises
|
8000 | |
| CY2020Q1 | us-gaap |
Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
|
91000 | |
| CY2018Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
149122000 | |
| CY2019Q1 | grts |
Lapse Of Repurchase Rights Related To Common Stock Issued Pursuant To Early Exercises
LapseOfRepurchaseRightsRelatedToCommonStockIssuedPursuantToEarlyExercises
|
17000 | |
| CY2019Q1 | us-gaap |
Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
|
86000 | |
| CY2019Q1 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
1007000 | |
| CY2020Q1 | us-gaap |
Depreciation And Amortization
DepreciationAndAmortization
|
1626000 | |
| CY2019Q1 | us-gaap |
Depreciation And Amortization
DepreciationAndAmortization
|
1036000 | |
| CY2020Q1 | us-gaap |
Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
|
78000 | |
| CY2019Q1 | us-gaap |
Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
|
519000 | |
| CY2020Q1 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
1619000 | |
| CY2019Q1 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
1007000 | |
| CY2020Q1 | us-gaap |
Operating Lease Cost
OperatingLeaseCost
|
1850000 | |
| CY2019Q1 | us-gaap |
Operating Lease Cost
OperatingLeaseCost
|
1344000 | |
| CY2020Q1 | us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
-32000 | |
| CY2019Q1 | us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
-778000 | |
| CY2020Q1 | grts |
Increase Decrease In Deposit And Other Assets Noncurrent
IncreaseDecreaseInDepositAndOtherAssetsNoncurrent
|
-83000 | |
| CY2019Q1 | grts |
Increase Decrease In Deposit And Other Assets Noncurrent
IncreaseDecreaseInDepositAndOtherAssetsNoncurrent
|
389000 | |
| CY2020Q1 | us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
865000 | |
| CY2019Q1 | us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
-235000 | |
| CY2020Q1 | us-gaap |
Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
|
-1825000 | |
| CY2019Q1 | us-gaap |
Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
|
-2257000 | |
| CY2020Q1 | grts |
Increase Decrease In Accrued And Other Liabilities Non Current
IncreaseDecreaseInAccruedAndOtherLiabilitiesNonCurrent
|
-38000 | |
| CY2019Q1 | grts |
Increase Decrease In Accrued And Other Liabilities Non Current
IncreaseDecreaseInAccruedAndOtherLiabilitiesNonCurrent
|
104000 | |
| CY2020Q1 | grts |
Increase Decrease In Accrued Research And Development Expenses
IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses
|
532000 | |
| CY2019Q1 | us-gaap |
Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
|
-1347000 | |
| CY2019Q1 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-19127000 | |
| CY2020Q1 | us-gaap |
Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
|
3805000 | |
| CY2019Q1 | us-gaap |
Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
|
9592000 | |
| CY2020Q1 | grts |
Proceeds From Maturity Of Marketable Securities
ProceedsFromMaturityOfMarketableSecurities
|
17167000 | |
| CY2019Q1 | grts |
Proceeds From Maturity Of Marketable Securities
ProceedsFromMaturityOfMarketableSecurities
|
13600000 | |
| CY2020Q1 | grts |
Proceeds From Sale Of Marketable Securities
ProceedsFromSaleOfMarketableSecurities
|
3021000 | |
| CY2020Q1 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
1609000 | |
| CY2019Q1 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
2578000 | |
| CY2020Q1 | us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
14774000 | |
| CY2019Q1 | us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
1430000 | |
| CY2020Q1 | us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
5659000 | |
| CY2019Q1 | us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
86000 | |
| CY2020Q1 | us-gaap |
Payments Of Financing Costs
PaymentsOfFinancingCosts
|
4000 | |
| CY2020Q1 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
5655000 | |
| CY2019Q1 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
86000 | |
| CY2020Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
-2548000 | |
| CY2019Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
-17611000 | |
| CY2019Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
58400000 | |
| CY2018Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
53175000 | |
| CY2020Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
55852000 | |
| CY2019Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
35564000 | |
| CY2020Q1 | us-gaap |
Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
|
946000 | |
| CY2019Q1 | us-gaap |
Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
|
513000 | |
| CY2019Q1 | grts |
Remeasurement Of Operating Lease Right Of Use Assets For Lease Modification
RemeasurementOfOperatingLeaseRightOfUseAssetsForLeaseModification
|
1779000 | |
| CY2020Q1 | us-gaap |
Use Of Estimates
UseOfEstimates
|
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.67%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and judgments that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities as of the date of the condensed financial statements and the reported amounts of revenue and expenses in the condensed financial statements and accompanying notes during the reporting period. On an ongoing basis, management evaluates its estimates, including those related to preclinical and clinical study trial accruals, fair value of assets and liabilities, the fair value of right-of-use assets (“ROU assets”) and lease liabilities, revenue recognition, and the fair value of stock-based compensation. Management bases its estimates on historical experience and on various other market-specific and relevant assumptions that management believes to be reasonable under the circumstances. Actual results could differ from those estimates.</p> | |
| CY2020Q1 | us-gaap |
Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
|
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Concentrations of Credit Risk</p> <p style="margin-top:6pt;margin-bottom:0pt;margin-right:0.93%;text-indent:6%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash, cash equivalents, and marketable securities. Cash, cash equivalents and marketable securities are invested through banks and other financial institutions in the United States. Such deposits may be in excess of federally insured limits. The Company maintains cash equivalents and marketable securities with various high-credit-quality and capitalized financial institutions. The Company has not experienced any credit losses in such accounts and does not believe it is exposed to any significant credit risk on these funds.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:6%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company’s investment policy limits investments to certain types of securities issued by the U.S. government, its agencies, and institutions with investment-grade credit ratings and places restrictions on maturities and concentration by type and issuer. The Company is exposed to credit risk in the event of a default by the financial institutions holding its cash, cash equivalents, and marketable securities and issuers of marketable securities to the extent recorded on the balance sheets. Through March 31, 2020, the Company has no off-balance sheet concentrations of credit risk<font style="color:#000000;">.</font></p> | |
| CY2020Q1 | us-gaap |
Number Of Operating Segments
NumberOfOperatingSegments
|
1 | |
| CY2020Q1 | grts |
Cash Cash Equivalents And Marketable Securities
CashCashEquivalentsAndMarketableSecurities
|
108900000 | |
| CY2019Q4 | grts |
Cash Cash Equivalents And Marketable Securities
CashCashEquivalentsAndMarketableSecurities
|
127800000 | |
| CY2020Q1 | us-gaap |
Other Assets Current
OtherAssetsCurrent
|
367000 | |
| CY2020Q1 | us-gaap |
Restricted Cash
RestrictedCash
|
992000 | |
| CY2019Q4 | us-gaap |
Restricted Cash
RestrictedCash
|
992000 | |
| CY2020Q1 | us-gaap |
Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
|
55852000 | |
| CY2019Q4 | us-gaap |
Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
|
58400000 | |
| CY2020Q1 | grts |
Cash Equivalents And Available For Sale Debt Securities Amortized Cost Basis
CashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis
|
101310000 | |
| CY2020Q1 | grts |
Cash Equivalents And Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
CashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
|
43000 | |
| CY2020Q1 | us-gaap |
Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
|
63000 | |
| CY2020Q1 | grts |
Cash Equivalents And Available For Sale Securities Debt Securities
CashEquivalentsAndAvailableForSaleSecuritiesDebtSecurities
|
101290000 | |
| CY2019Q4 | grts |
Cash Equivalents And Available For Sale Debt Securities Amortized Cost Basis
CashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis
|
116726000 | |
| CY2019Q4 | grts |
Cash Equivalents And Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
CashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
|
30000 | |
| CY2019Q4 | us-gaap |
Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
|
6000 | |
| CY2019Q4 | grts |
Cash Equivalents And Available For Sale Securities Debt Securities
CashEquivalentsAndAvailableForSaleSecuritiesDebtSecurities
|
116750000 | |
| CY2020Q1 | grts |
Marketable Securities Realized Gain Loss Description
MarketableSecuritiesRealizedGainLossDescription
|
no material realized gains or losses | |
| CY2020Q1 | us-gaap |
Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Number Of Positions
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions
|
33 | |
| CY2020Q1 | us-gaap |
Provision For Loan Losses Expensed
ProvisionForLoanLossesExpensed
|
0 | |
| CY2020Q1 | us-gaap |
Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
|
0 | |
| CY2019Q4 | us-gaap |
Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
|
0 | |
| CY2020Q1 | us-gaap |
Fair Value Liabilities Level1 To Level2 Transfers Amount
FairValueLiabilitiesLevel1ToLevel2TransfersAmount
|
0 | |
| CY2019Q4 | us-gaap |
Fair Value Liabilities Level1 To Level2 Transfers Amount
FairValueLiabilitiesLevel1ToLevel2TransfersAmount
|
0 | |
| CY2020Q1 | us-gaap |
Fair Value Assets Level2 To Level1 Transfers Amount
FairValueAssetsLevel2ToLevel1TransfersAmount
|
0 | |
| CY2019Q4 | us-gaap |
Fair Value Assets Level2 To Level1 Transfers Amount
FairValueAssetsLevel2ToLevel1TransfersAmount
|
0 | |
| CY2020Q1 | us-gaap |
Fair Value Liabilities Level2 To Level1 Transfers Amount
FairValueLiabilitiesLevel2ToLevel1TransfersAmount
|
0 | |
| CY2019Q4 | us-gaap |
Fair Value Liabilities Level2 To Level1 Transfers Amount
FairValueLiabilitiesLevel2ToLevel1TransfersAmount
|
0 | |
| CY2020Q1 | us-gaap |
Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
|
37782000 | |
| CY2019Q4 | us-gaap |
Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
|
37221000 | |
| CY2020Q1 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
11935000 | |
| CY2019Q4 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
10310000 | |
| CY2020Q1 | us-gaap |
Short Term Lease Cost
ShortTermLeaseCost
|
8000 | |
| CY2019Q1 | us-gaap |
Short Term Lease Cost
ShortTermLeaseCost
|
56000 | |
| CY2020Q1 | us-gaap |
Lease Cost
LeaseCost
|
1858000 | |
| CY2019Q1 | us-gaap |
Lease Cost
LeaseCost
|
1400000 | |
| CY2020Q1 | us-gaap |
Operating Lease Payments
OperatingLeasePayments
|
1053000 | |
| CY2019Q1 | us-gaap |
Operating Lease Payments
OperatingLeasePayments
|
640000 | |
| CY2019Q1 | us-gaap |
Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
|
10542000 | |
| CY2020Q1 | us-gaap |
Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
|
P6Y10M24D | |
| CY2019Q1 | us-gaap |
Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
|
P7Y7M6D | |
| CY2020Q1 | us-gaap |
Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
|
0.090 | |
| CY2019Q1 | us-gaap |
Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
|
0.090 | |
| CY2020Q1 | us-gaap |
Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
|
4311000 | |
| CY2020Q1 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
|
6360000 | |
| CY2020Q1 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
|
3740000 | |
| CY2020Q1 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
|
3459000 | |
| CY2020Q1 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
|
3449000 | |
| CY2020Q1 | us-gaap |
Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
|
12531000 | |
| CY2020Q1 | us-gaap |
Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
|
33850000 | |
| CY2020Q1 | us-gaap |
Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
|
9273000 | |
| CY2020Q1 | grts |
Operating Lease Tenant Improvement Allowance
OperatingLeaseTenantImprovementAllowance
|
1055000 | |
| CY2020Q1 | us-gaap |
Operating Lease Liability
OperatingLeaseLiability
|
23522000 | |
| CY2020Q1 | us-gaap |
Prepaid Insurance
PrepaidInsurance
|
834000 | |
| CY2019Q4 | us-gaap |
Prepaid Insurance
PrepaidInsurance
|
1252000 | |
| CY2020Q1 | grts |
Interest And Other Receivables Current
InterestAndOtherReceivablesCurrent
|
662000 | |
| CY2019Q4 | grts |
Interest And Other Receivables Current
InterestAndOtherReceivablesCurrent
|
482000 | |
| CY2020Q1 | grts |
Prepaid Expense For Research And Development
PrepaidExpenseForResearchAndDevelopment
|
1603000 | |
| CY2019Q4 | grts |
Prepaid Expense For Research And Development
PrepaidExpenseForResearchAndDevelopment
|
1473000 | |
| CY2019Q4 | us-gaap |
Other Assets Current
OtherAssetsCurrent
|
290000 | |
| CY2019Q4 | us-gaap |
Security Deposit
SecurityDeposit
|
1201000 | |
| CY2020Q1 | grts |
Prepaid Expense For Research And Development Non Current
PrepaidExpenseForResearchAndDevelopmentNonCurrent
|
502000 | |
| CY2020Q1 | us-gaap |
Security Deposit
SecurityDeposit
|
1201000 | |
| CY2019Q4 | grts |
Prepaid Expense For Research And Development Non Current
PrepaidExpenseForResearchAndDevelopmentNonCurrent
|
585000 | |
| CY2020Q1 | us-gaap |
Restricted Cash Noncurrent
RestrictedCashNoncurrent
|
992000 | |
| CY2019Q4 | us-gaap |
Restricted Cash Noncurrent
RestrictedCashNoncurrent
|
992000 | |
| CY2020Q1 | grts |
Accrued Property And Equipment Current
AccruedPropertyAndEquipmentCurrent
|
192000 | |
| CY2019Q4 | grts |
Accrued Property And Equipment Current
AccruedPropertyAndEquipmentCurrent
|
761000 | |
| CY2020Q1 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
222000 | |
| CY2019Q4 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
280000 | |
| CY2019Q4 | us-gaap |
Contract With Customer Liability
ContractWithCustomerLiability
|
14516000 | |
| CY2020Q1 | grts |
Contract With Customer Liability Addition
ContractWithCustomerLiabilityAddition
|
0 | |
| CY2020Q1 | us-gaap |
Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
|
-917000 | |
| CY2020Q1 | us-gaap |
Contract With Customer Liability
ContractWithCustomerLiability
|
13599000 | |
| CY2020Q1 | us-gaap |
Common Stock Voting Rights
CommonStockVotingRights
|
Holders of the Company’s common stock are entitled to one vote per share. | |
| CY2019Q4 | grts |
Maximum Securities Covered Under Registration Agreement
MaximumSecuritiesCoveredUnderRegistrationAgreement
|
250000000 | |
| CY2019Q4 | grts |
Percentage Of Proceeds Payable As Compensation To Underwriter
PercentageOfProceedsPayableAsCompensationToUnderwriter
|
0.030 | |
| CY2019Q4 | grts |
Maximum Offering Expenses Agreed To Be Reimbursed
MaximumOfferingExpensesAgreedToBeReimbursed
|
50000 | |
| CY2019Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
|
2851883 | |
| CY2020Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
|
1454553 | |
| CY2020Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
|
1543300 | |
| CY2020Q1 | grts |
Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Exercised
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantExercised
|
0 | |
| CY2020Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
|
32230 | |
| CY2020Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
|
2795366 | |
| CY2019Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
3165961 | |
| CY2020Q1 | us-gaap |
Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
|
60682 | |
| CY2020Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
4616349 | |
| CY2020Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
|
1259277 | |
| CY2020Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
|
4137336 | |
| CY2019Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
|
7.83 | |
| CY2020Q1 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
|
8.91 | |
| CY2020Q1 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
|
1.50 | |
| CY2020Q1 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
|
9.71 | |
| CY2020Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
|
8.26 | |
| CY2020Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
|
5.70 | |
| CY2020Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
|
8.09 | |
| CY2019 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
|
P8Y5M12D | |
| CY2020Q1 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
|
P8Y9M10D | |
| CY2020Q1 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
|
P7Y8M23D | |
| CY2020Q1 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
|
P8Y8M15D | |
| CY2019Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
|
8875000 | |
| CY2020Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
|
4664000 | |
| CY2020Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
|
3242000 | |
| CY2020Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
|
4614000 | |
| CY2020Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
|
400000 | |
| CY2019Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
|
2000000 | |
| CY2020Q1 | us-gaap |
Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
|
17300000 | |
| CY2020Q1 | us-gaap |
Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
|
P3Y14D | |
| CY2020Q1 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
|
1200000 | |
| CY2020Q1 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
1619000 | |
| CY2019Q1 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
1007000 | |
| CY2020Q1 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
4654583 | |
| CY2019Q4 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
3209915 |
